We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $45.1M
1-Year Est. Return 74.25%
This Fund
S&P 500
This Quarter Est. Return
-3.5%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$1.82B
AUM Growth
-$609M
Cap. Flow
-$347M
Cap. Flow %
-19.1%
Top 10 Hldgs %
52.59%
Holding
435
New
56
Increased
93
Reduced
114
Closed
122

Top Buys

Rank Stock Value
1
ALKS icon
Alkermes
ALKS
+$9.22M
2
TBRA
Tobira Therapeutics, Inc. Common Stock
TBRA
+$7.3M
3
GWPH
GW Pharmaceuticals Plc American Depositary Shares
GWPH
+$7.22M
4
UTHR icon
United Therapeutics
UTHR
+$5.06M
5
LUMO
Lumos Pharma, Inc. Common Stock
LUMO
+$4.98M

Top Sells

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$22.6M
2
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$18.2M
3
VTRS icon
Viatris
VTRS
+$18.1M
4
PXD
Pioneer Natural Resource Co.
PXD
+$15M
5
EW icon
Edwards Lifesciences
EW
+$11.6M

Sector Composition

Rank Sector Weight
1 Healthcare 10.47%
2 Technology 0.45%
3 Consumer Staples 0.1%
4 Industrials 0.09%
5 Materials 0.03%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PHG icon
51
CALL
Philips
PHG
$25B
$6.04M 0.33%
3,317
– –
BLCM
52
CALL
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
$5.93M 0.33%
293
+240
+453% +$42.9K
VXZ
53
DELISTED
iPath S&P 500 VIX Mid-Term Futures ETN due 1/30/2019
VXZ
$5.85M 0.32%
131,283
+18,658
+17% +$844K
BLUE
54
CALL
DELISTED
bluebird bio
BLUE
$5.53M 0.3%
66
-3
-4% -$3K
UTHR icon
55
United Therapeutics
UTHR
$26.1B
$5.45M 0.3%
+34,779
New +$5.06M
NVRO
56
PUT
DELISTED
NEVRO CORP.
NVRO
$5.39M 0.3%
798
+53
+7% +$2.84K
ACAD icon
57
CALL
Acadia Pharmaceuticals
ACAD
$4.45B
$5.31M 0.29%
1,489
+51
+4% +$1.8K
MNKD icon
58
CALL
MannKind Corp
MNKD
$1.21B
$5.15M 0.28%
7,107
+921
+15% +$11.3K
NVO
59
CALL
Novo Nordisk
NVO
$225B
$5.05M 0.28%
+1,740
New +$48.2K
KITE
60
PUT
DELISTED
Kite Pharma, Inc.
KITE
$4.98M 0.27%
808
-1,015
-56% -$71.4K
BMRN icon
61
PUT
BioMarin Pharmaceuticals
BMRN
$12B
$4.98M 0.27%
475
-2,436
-84% -$254K
THC icon
62
CALL
Tenet Healthcare
THC
$22.6B
$4.68M 0.26%
1,545
-6,200
-80% -$203K
DVAX
63
CALL
DELISTED
Dynavax Technologies
DVAX
$4.61M 0.25%
1,907
-166
-8% -$4.16K
OPK icon
64
CALL
Opko Health
OPK
$1.23B
$4.52M 0.25%
4,500
– –
ALKS icon
65
CALL
Alkermes
ALKS
$8.47B
$4.51M 0.25%
568
+31
+6% +$2.17K
ABUS icon
66
Arbutus Biopharma
ABUS
$871M
$4.45M 0.24%
1,000,000
+274,993
+38% +$1.51M
VRTX icon
67
CALL
Vertex Pharmaceuticals
VRTX
$124B
$4.29M 0.24%
341
– –
PCRX icon
68
CALL
Pacira BioSciences
PCRX
$1.05B
$4.25M 0.23%
+553
New +$31.3K
HCA icon
69
CALL
HCA Healthcare
HCA
$92.8B
$4.22M 0.23%
624
– –
INO icon
70
Inovio Pharmaceuticals
INO
$84.7M
$4.16M 0.23%
51,599
-9,864
-16% -$785K
ACAD icon
71
Acadia Pharmaceuticals
ACAD
$4.45B
$4.06M 0.22%
+113,838
New +$4.01M
ALPN
72
DELISTED
Alpine Immune Sciences Inc
ALPN
$3.9M 0.21%
125,899
+29,715
+31% +$1.01M
ASXC
73
CALL
DELISTED
Asensus Surgical, Inc.
ASXC
$3.84M 0.21%
1,191
+420
+54% +$13.5K
ASXC
74
DELISTED
Asensus Surgical, Inc.
ASXC
$3.77M 0.21%
117,039
-5,355
-4% -$172K
CELG
75
CALL
DELISTED
Celgene Corp
CELG
$3.75M 0.21%
+313
New +$36.2K
1 2
3
4 5

Similar funds

CG
Circumference Group Little Rock, Arkansas $44.6M AUM 5.21% 1-Year Est. Return
OC
Optimas Capital Central, Hong Kong $44.5M AUM 24.43% 1-Year Est. Return
ICCON
Investment Counsel Company of Nevada Las Vegas, Nevada $44.5M AUM 21.97% 1-Year Est. Return
PCM
Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
CTC
Corundum Trust Company Sioux Falls, South Dakota $43.8M AUM 20.07% 1-Year Est. Return

Sabby Management's Q4 2015 Portfolio in Review

As of Q4 2015, Sabby Management held 435 positions worth $1.82B, down 25% from $2.43B the previous quarter. Its ten largest holdings account for 53% of the portfolio.

Sabby Management withdrew a net $347M in Q4 2015, closing 122 positions and reducing 114 holdings. Its most notable exit was Biogen, an estimated $22.6M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 10% of assets, down from 13% a quarter earlier, followed by Technology and Consumer Staples.

Against the trend, Sabby Management opened a new position in Alkermes worth $10.5M.

  • Sabby Management's largest Q4 2015 buy was Alkermes: 131,671 shares worth $10.5M.
  • Sabby Management added most to Tobira Therapeutics, Inc. Common Stock in Q4 2015, an estimated $7.3M increase.
  • Sabby Management's biggest Q4 2015 reduction was Edwards Lifesciences, cutting an estimated $11.6M.
  • Sabby Management fully exited Biogen in Q4 2015, selling an estimated $22.6M.
  • Sabby Management's ten largest holdings make up 53% of its $1.82B portfolio in Q4 2015.
  • Sabby Management opened 56 new positions and closed 122 in Q4 2015.
  • Sabby Management's portfolio value fell 25% quarter-over-quarter to $1.82B.

Based on Sabby Management's 13F filing for Q4 2015, filed 16 Feb 2016.